The decades-long quest to harness the power of messenger RNA to enhance cancer treatment has focused primarily on its value ...
Standardized evaluation protocol improved transfer, ECSL outcomes, and re-transfer to discharge for pediatric hematologic oncology patients.
Prelude Therapeutics Incorporated (Nasdaq: PRLD) (“Prelude” or the “Company”), a clinical-stage precision oncology company, ...
Mandy Lauw, MD, PhD, recently honored with first-ever Young EHA Award, advocates for bigger roles for early-career clinicians ...
The upgrade followed Incyte Corp.’s (NASDAQ:INCY) third quarter earnings results last week, where it quadrupled its net ...
PureTech to Present New Data from Ongoing Phase 1b Trial of LYT-200 in Relapsed/Refractory Acute Myeloid Leukemia (AML) at ASH Annual Meeting ...
The abstract, titled “Data-driven subtyping and differential glufosfamide benefit in pancreatic adenocarcinoma,” will be featured in Poster Session B on January 9. It will also be published in the ...
Panelists discussed these questions during a recent Institute for Value-Based Medicine® event held in Nashville, Tennessee, ...
Secura Bio, Inc. ( an integrated pharmaceutical company maximizing commercial outcomes for oncology medicines, today announced a poster presentation highlighting extended follow up analyses examining ...
Equitable access to genomic testing for NSCLC patients is vital for advanced therapy access, with strategies including ...
Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines in oncology ...
Recordati Rare Diseases Inc. today announced the presentation of new data related to its growing portfolio of treatments for rare hematologic disorders at the 67th American Society of Hematology (ASH) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback